Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting
October 03 2016 - 4:12PM
Emricasan Improves Liver Function in
Cirrhosis Patients with NASH and/or Elevated MELD
Scores
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that
abstracts for four posters – two addressing clinical results and
two addressing preclinical results with the company’s pan-caspase
inhibitor, emricasan – have been accepted for presentation at The
Liver Meeting®, the annual meeting of the American Association for
the Study of Liver Diseases (AASLD) in Boston November 11-15, 2016.
Accepted abstracts were published today on the AASLD website at
www.aasld.org/ for posters entitled:
- “Emricasan (IDN-6556) Orally for 6 Months in Patients with
Cirrhosis and Elevated MELD Score Improves Liver Function,” (poster
#2095);
- “Emricasan (IDN-6556) Orally for 6 Months in Patients with
Non-alcoholic Steatohepatitis (NASH) Cirrhosis Decreases the
Progression of MELD score and Improves Liver Function,” (poster
#2099);
- “Circulating microparticles carry apoptosis markers CK-18 and
caspase-3/7 which are reduced by treatment with Emricasan in
subjects with chronic liver diseases,” (poster #2098); and
- “The pan caspase inhibitor Emricasan improves the hepatic
microcirculatory dysfunction of CCl4-cirrhotic rats leading to
portal hypertension amelioration and cirrhosis regression,” (poster
#2097).
- Both poster #2095 and poster #2097 were accepted as
“Presidential Posters of Distinction,” indicating review scores
that place them within the top 10 percent of all posters
submitted.
“We continue accumulating clinical evidence of emricasan’s
disease-modifying potential as we advance toward an initial
registration in patients with liver cirrhosis caused by
nonalcoholic steatohepatitis (NASH),” said Conatus co-founder,
President and Chief Executive Officer Steven J. Mento, Ph.D.,
“while simultaneously confirming emricasan’s multiple mechanistic
effects on liver structure and function through preclinical
studies. We are pleased with the opportunity to highlight the
latest developments in both areas at the upcoming AASLD meeting,
providing a deeper scientific understanding of the medical benefits
observed in our clinical trials.”
About Emricasan Clinical DevelopmentTo date,
emricasan has been studied in over 650 subjects in sixteen clinical
trials across a broad range of liver disease etiologies and stages
of progression. In multiple clinical trials, emricasan has
demonstrated statistically significant, rapid and sustained
reductions in elevated levels of key biomarkers of inflammation and
apoptosis that are implicated in the progression of liver disease.
Recent clinical trial results have demonstrated emricasan’s ability
to provide statistically significant improvements in clinically
important validated functional surrogate endpoints of portal
hypertension and liver function across a variety of etiologies in
the subgroups of liver cirrhosis patients with highest medical
need. The company has initiated ENCORE-NF, the first among its
planned set of parallel EmricasaN, a Caspase inhibitOR, for
Evaluation (ENCORE) clinical trials designed to evaluate multiple
doses of emricasan over various treatment durations in chronic
liver disease of different etiologies and disease stages. The
ENCORE trials are designed to provide further information on doses
leading to clinically relevant efficacy, including improvement in
biopsy-proven fibrosis and inflammation in patients with NASH
fibrosis, and improvement in severe portal hypertension and hepatic
function in patients with NASH cirrhosis. The ENCORE trials are
also designed to provide safety data to support the initial
registration of emricasan for chronic administration in patients
with NASH cirrhosis. The company’s recently initiated Phase 2b
ENCORE-NF clinical trial is evaluating emricasan’s potential
longer-term benefits for patients with NASH fibrosis. The company
also is evaluating emricasan’s potential longer-term benefits on
liver fibrosis and cirrhosis in its ongoing Phase 2b clinical trial
in post-orthotopic liver transplant (POLT) recipients who developed
liver fibrosis or cirrhosis post-transplant as a result of
recurrent hepatitis C virus (HCV) infection and who have
successfully achieved a sustained viral response (SVR) following
antiviral therapy (POLT-HCV-SVR).
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease.
Conatus is developing its lead compound, emricasan, for the
treatment of patients with chronic liver disease. Emricasan is a
first-in-class, orally active pan-caspase inhibitor designed to
reduce the activity of enzymes that mediate inflammation and
apoptosis. Conatus believes that by reducing the activity of these
enzymes, emricasan has the potential to interrupt the disease
progression across the spectrum of liver disease. For additional
information, please visit www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward looking statements, including
statements regarding: the company’s plans to conduct the
ENCORE set of parallel clinical trials; the ability of the ENCORE
trials to provide dosing information leading to clinically relevant
efficacy in patients with NASH fibrosis and NASH cirrhosis, and
safety data to support the initial registration of emricasan for
chronic administration; emricasan’s potential longer-term benefits
for patients with NASH fibrosis; emricasan’s potential longer-term
benefits on liver fibrosis and cirrhosis in POLT-HCV-SVR patients;
and emricasan’s potential to interrupt the disease progression
across the spectrum of liver disease. In some cases, you can
identify forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplates,” “believes,” “estimates,”
“predicts,” “potential” or “continue” or the negative of these
terms or other similar expressions. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including: Conatus’ ability to initiate and successfully
complete current and future clinical trials; and those risks
described in Conatus’ prior press releases and in the periodic
reports it files with the Securities and Exchange
Commission. The events and circumstances reflected in Conatus’
forward-looking statements may not be achieved or occur and actual
results could differ materially from those projected in the
forward-looking statements. Except as required by applicable law,
Conatus does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
MEDIA: David Schull
Russo Partners, LLC
(858) 717-2310
David.Schull@RussoPartnersLLC.com
INVESTORS: Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2024 to May 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From May 2023 to May 2024